Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

SoFis quarterly earnings and outlook are the dominant focus, with traders weighing growth against credit quality and funding costs. The community is split between hopes that strong results or firmer guidance could improve sentiment and concerns that the stock may sell off again even if it beats expectations.

A major financing arrangement to supply Broadcom AI accelerators and networking gear to Anthropic is driving attention, with traders viewing it as a signal of long-term demand. The community is divided between optimism about demand visibility and concern over Broadcoms financing exposure and the stocks continued weakness.

Lulas reelection has triggered a sharp selloff across Brazilian assets, with traders linking XPs steep decline to concerns about government spending, fiscal discipline and the weaker real rather than a company-specific development. The community is split between calling the move an overreaction and buying for a rebound, and warning that political and currency risks could keep pressure on the shares.

Baidu is drawing attention amid a prolonged selloff in Chinese tech and repeated 52-week lows, with traders pointing to weak market flows, limited stimulus and thin buying interest. Some see a value trap and expect further declines, while dip buyers cite oversold conditions, buybacks and a possible Kunlunxin IPO as reasons for optimism; the IPO remains speculative.

Cornings upcoming third-quarter earnings report is the main focus, with traders weighing expectations for continued optical and AI-fiber demand against concern about repeated post-earnings declines and elevated volatility. Bullish earnings bets and call activity are notable, but sentiment remains divided on the risk of another selloff.

BETR is drawing attention amid a sharp rally that traders link to the companys share repurchases and a reportedly tight float with substantial short interest. Many are speculating about a short or options-driven squeeze, while others question whether trading volume and buying pressure are sufficient to sustain one.

Discussion centers on Bittensors decentralized-AI thesis and reported growth in subnet revenue, with Jason Calacaniss public backing adding visibility. Many traders express long-term conviction and buy the pullback, while others question whether subnet activity will translate into sustainable demand and value for TAO holders.

Helus Pharma is drawing attention ahead of topline Phase 3 results for HLP003 in major depressive disorder, with traders focused on whether the readout will validate the earlier results and the drugs add-on approach alongside existing antidepressants. Optimistic expectations and insider-buying discussion contrast with concerns about the trials binary risk, possible dilution, and recent share-price weakness.

CEO Paul Gus reported open-market share purchase has drawn attention, with bullish traders treating it as a confidence signal near the stocks lows. Skeptics argue the buying does little to offset concerns about Upstarts debt, sensitivity to interest rates and prolonged share-price decline.

Attention centers on the anticipated final analysis of SELLASs Phase 3 REGAL trial of GPS in AML, which is triggered by 80 patient events; traders are focused on the gap since the last disclosed count of 78 and speculate about when results may be shared, including around ASH. Bulls interpret the prolonged wait as a possible sign of longer survival, while skeptics say the delay and lack of data leave the trials outcome uncertain.